Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease

被引:52
作者
Lorenzen, Johan [1 ]
Kraemer, Robert
Kliem, Volker [2 ]
Bode-Boeger, Stefanie M. [3 ]
Veldink, Hendrik
Haller, Hermann
Fliser, Danilo [4 ]
Kielstein, Jan T.
机构
[1] Hannover Med Sch, Div Nephrol & Hypertens, Dept Internal Med, D-30625 Hannover, Germany
[2] Nephrol Ctr Lower Saxony, Munden, Germany
[3] Otto Von Guericke Univ, D-39016 Magdeburg, Germany
[4] Univ Saarland, Med Ctr, D-6650 Homburg, Germany
关键词
ADMA; atherosclerosis; osteopontin; renal function; SDMA; vascular calcification; PROMATRIX METALLOPROTEINASE-9 ACTIVATION; BLOOD-PRESSURE RESEARCH; ASYMMETRIC DIMETHYLARGININE; SYMMETRIC DIMETHYLARGININE; MESSENGER-RNA; CELL; ALPHA-V-BETA-3; CALCIFICATION; EPIDEMIOLOGY; INFLAMMATION;
D O I
10.1111/j.1365-2362.2010.02271.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Background The pleiotropic cytokine osteopontin (OPN) is thought to be involved in the pathogenesis of atherosclerosis. However, the relationship between OPN and renal function, a cardiovascular risk factor itself, is not known. Therefore, we assessed the relationship between OPN plasma levels and renal function in patients at different stages of chronic kidney disease (CKD). Methods We studied 49 non-diabetic and non-smoking patients with primary kidney disease at different CKD stages (K/DOQI 1-5). True glomerular filtration rate (GFR) in patients was assessed using the inulin-clearance technique. To examine the role of an abrupt change in GFR on circulating OPN, 15 living related kidney donors were studied before and after unilateral nephrectomy. Twenty matched non-smoking healthy subjects served as controls. Results OPN plasma levels in patients with CKD stage 1 (i.e. GFR above 90 mL min-1 1 center dot 73 m-2) were comparable with controls. OPN levels increase in a linear fashion with declining GFR (r = -0 center dot 9, P < 0 center dot 0001), so that the increase in OPN mirrors the severity of renal impairment. After unilateral nephrectomy, circulating OPN increased significantly in parallel to the decrease in GFR. We found a direct association between OPN and other markers of renal function (serum-creatinine, homocysteine and symmetric dimethylarginine,) as well as with cardiovascular risk factors such as asymmetric dimethylarginine (r = 0 center dot 36, P = 0 center dot 0213). Conclusion There is a close inverse association between GFR and circulating OPN in patients with CKD. Furthermore, OPN plasma levels correlate with established cardiovascular risk markers in patients with CKD. Assessment of renal function is important for the interpretation of OPN levels in patients with atherosclerotic disease.
引用
收藏
页码:294 / 300
页数:7
相关论文
共 38 条
  • [1] Analysis of the α4β1 integrin-osteopontin interaction
    Barry, ST
    Ludbrook, SB
    Murrison, E
    Horgan, CMT
    [J]. EXPERIMENTAL CELL RESEARCH, 2000, 258 (02) : 342 - 351
  • [2] Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-An update on patient populations with a wide range of cardiovascular risk
    Boeger, Rainer H.
    Maas, Renke
    Schulze, Friedrich
    Schwedhelm, Edzard
    [J]. PHARMACOLOGICAL RESEARCH, 2009, 60 (06) : 481 - 487
  • [3] Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community
    Boeger, Rainer H.
    Sullivan, Lisa M.
    Schwedhelm, Edzard
    Wang, Thomas J.
    Maas, Renke
    Benjamin, Emelia J.
    Schulze, Friedrich
    Xanthakis, Vanessa
    Benndorf, Ralf A.
    Vasan, Ramachandran S.
    [J]. CIRCULATION, 2009, 119 (12) : 1592 - U65
  • [4] Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease - A science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the councils on high blood pressure research, cardiovascular disease in the young, and epidemiology and prevention; and the quality of care and outcomes research interdisciplinary working group
    Brosius, Frank C., III
    Hostetter, Thomas H.
    Kelepouris, Ellie
    Mitsnefes, Mark M.
    Moe, Sharon M.
    Moore, Michael A.
    Pennathur, Subramaniam
    Smith, Grace L.
    Wilson, Peter W. F.
    [J]. CIRCULATION, 2006, 114 (10) : 1083 - 1087
  • [5] Prevalence of chronic kidney disease in the United States
    Coresh, Josef
    Selvin, Elizabeth
    Stevens, Lesley A.
    Manzi, Jane
    Kusek, John W.
    Eggers, Paul
    Van Lente, Frederick
    Levey, Andrew S.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (17): : 2038 - 2047
  • [6] OSTEOPONTIN OVEREXPRESSION IS ASSOCIATED WITH ARTERIAL SMOOTH-MUSCLE CELL-PROLIFERATION INVITRO
    GADEAU, AP
    CAMPAN, M
    MILLET, D
    CANDRESSE, T
    DESGRANGES, C
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (01): : 120 - 125
  • [7] MOLECULAR-CLONING AND CHARACTERIZATION OF 2B7, A RAT MESSENGER-RNA WHICH DISTINGUISHES SMOOTH-MUSCLE CELL PHENOTYPES INVITRO AND IS IDENTICAL TO OSTEOPONTIN (SECRETED PHOSPHOPROTEIN-I, 2AR)
    GIACHELLI, C
    BAE, N
    LOMBARDI, D
    MAJESKY, M
    SCHWARTZ, S
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 177 (02) : 867 - 873
  • [8] OSTEOPONTIN IS ELEVATED DURING NEOINTIMA FORMATION IN RAT ARTERIES AND IS A NOVEL COMPONENT OF HUMAN ATHEROSCLEROTIC PLAQUES
    GIACHELLI, CM
    BAE, N
    ALMEIDA, M
    DENHARDT, DT
    ALPERS, CE
    SCHWARTZ, SM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (04) : 1686 - 1696
  • [9] Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin
    Ihara, H
    Denhardt, DT
    Furuya, K
    Yamashita, T
    Muguruma, Y
    Tsuji, K
    Hruska, KA
    Higashio, K
    Enomoto, S
    Nifuji, A
    Rittling, SR
    Noda, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) : 13065 - 13071
  • [10] OSTEOPONTIN MESSENGER-RNA IS EXPRESSED BY SMOOTH MUSCLE-DERIVED FOAM CELLS IN HUMAN ATHEROSCLEROTIC LESIONS OF THE AORTA
    IKEDA, T
    SHIRASAWA, T
    ESAKI, Y
    YOSHIKI, S
    HIROKAWA, K
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) : 2814 - 2820